Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys

Massri, Nabil El; Moro, Cécile; Torres, Napoléon; Darlot, Fannie; Agay, Diane; Chabrol, C.; Johnstone, Daniel M.; Stone, Jonathan; Benabid, Alim‐Louis; Mitrofanis, John

doi:10.1007/s00221-016-4720-7

Cited by 38 publications

(31 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned above, these authors also reported a protective effect of abscopal light exposure (head shielded) in this mouse model [33]. Recently this group has tested their implanted fiber approach in a model of Parkinson’s disease in adult Macaque monkeys treated with MPTP [86]. Clinical evaluation of Parkinson’s symptoms (posture, general activity, bradykinesia, and facial expression) in the monkeys were improved at low doses of light (24 J or 35 J) compared to high doses (125 J) [87].…”

Section: Parkinson’s Diseasementioning

confidence: 88%

Photobiomodulation and the brain: a new paradigm

Hennessy¹,

Hamblin

2016

J. Opt.

167

117

View full text Add to dashboard Cite

Transcranial photobiomodulation (PBM) also known as low level laser therapy (tLLLT) relies on the use of red/NIR light to stimulate, preserve and regenerate cells and tissues. The mechanism of action involves photon absorption in the mitochondria (cytochrome c oxidase), and ion channels in cells leading to activation of signaling pathways, up-regulation of transcription factors, and increased expression of protective genes. We have studied PBM for treating traumatic brain injury (TBI) in mice using a NIR laser spot delivered to the head. Mice had improved memory and learning, increased neuroprogenitor cells in the dentate gyrus and subventricular zone, increased BDNF and more synaptogenesis in the cortex. These highly beneficial effects on the brain suggest that the applications of tLLLT are much broader than at first conceived. Other groups have studied stroke (animal models and clinical trials), Alzheimer’s disease, Parkinson’s disease, depression, and cognitive enhancement in healthy subjects.

show abstract

Section: Parkinson’s Diseasementioning

confidence: 88%

Photobiomodulation and the brain: a new paradigm

Hennessy¹,

Hamblin

2016

J. Opt.

167

117

View full text Add to dashboard Cite

show abstract

“…56 PBMt has also demonstrated influence on the glial response, particularly that of the astrocytes, in a monkey model of Parkinson's disease. 57 Sun et al found that PBMt applied to the spinal cord of rats after SCI inhibited activation of GFAP-positive astrocytes as well as inhibited astrocyte proliferation and the expression of astrocyte activation-related genes in vitro. 58 Finally, there is one published study specifically examining the use of PBMt in an SOD1 transgenic mouse model of ALS.…”

Section: Photobiomodulation Parameters Light Transmission and Diffementioning

confidence: 99%

Retrospective Observational Study and Analysis of Two Different Photobiomodulation Therapy Protocols Combined with Rehabilitation Therapy as Therapeutic Interventions for Canine Degenerative Myelopathy

Miller¹,

Torraca²,

Taboada³

2020

Photobiomodulation, Photomedicine, and Laser Surgery

View full text Add to dashboard Cite

Objective: The objective of this retrospective review was to examine the impact that adding photobiomodulation therapy (PBMt) to rehabilitation therapy had on the pathology of degenerative myelopathy (DM) in canine patients. Background: Canine DM is a progressive, fatal neurodegenerative disease for which there exists a dearth of effective treatments, limiting clinicians to pursue symptom palliation. Methods: Clinical records of dogs referred for presumed DM to a specialty rehabilitation facility were screened for patients meeting study criteria. Qualifying patients were divided into two groups: Protocol A (PTCL-A) and Protocol B (PTCL-B) group, based on the PBMt protocol used. Data related to demographics, diagnostics, rehabilitation protocols, and progression of clinical signs were collected. Data were analyzed to determine differences in outcomes between the two treated groups and historical data expectations, as given by a previously published study. Results: The times between symptom onset and euthanasia of dogs in the PTCL-B group: 38.2-14.67 months (mean-SD), were significantly longer than those of dogs in the PTCL-A group: 11.09-2.68 months. Similarly, the times between symptom onset and nonambulatory paresis (NAP) or paralysis of dogs in the PTCL-B group: 31.76-12.53 months, were significantly longer than those of dogs in the PTCL-A group: 8.79-1.60 months. Further, Kaplan-Meier survival analysis showed that the times from symptom onset to NAP of dogs in the PTCL-B group were significantly longer than those of dogs in the PTCL-A group (Mantel-Cox Log Rank statistic = 20.434, p < 0.05) or the historical data group (Mantel-Cox Log Rank statistic = 16.334, p < 0.05). Conclusions: The data reviewed show significantly slower disease progression-longer survival times-for patients in the PTCL-B group than those in the PTCL-A group or published historical data. Further studies are warranted.

show abstract

“…Limited studies have shown the effect of 670 nm treatment following SCI on astrocyte activation or GFAP upregulation, although similar effects using 810 nm have been documented 22 . Other groups have previously demonstrated a reduction in GFAP expression following light treatment in Müller cells in the retina 62, 63 , and a decrease in GFAP expression by 670 nm irradiation in the brain of monkeys with Parkinson’s disease 64 . The present study is the first demonstration that astrocytic hypertrophy is reduced by daily 670 nm treatment from 3-dpi following SCI.…”

Section: Discussionmentioning

confidence: 93%

Red-light (670 nm) therapy reduces mechanical sensitivity and neuronal cell death, and alters glial responses following spinal cord injury in rats

Moalem‐Taylor

Potas

2020

Preprint

View full text Add to dashboard Cite

Individuals with spinal cord injury (SCI) often develop debilitating neuropathic pain, which may be driven by neuronal damage and neuroinflammation. We have previously demonstrated that treatment using 670 nm (red) light irradiation alters microglia/macrophage responses and alleviates mechanical hypersensitivity at 7-days post-injury. Here, we investigated the effect of red-light on the development of mechanical hypersensitivity, neuronal markers, and glial response in the subacute stage (days 1-7) following SCI. Wistar rats were subjected to a mild T10 hemi-contusion SCI or sham surgery followed by daily red-light treatment (30 min/day; 670 nm LED; 35mW/cm2) or sham treatment. Mechanical sensitivity of the rat dorsum was assessed from 1-day post-injury and repeated every second day. Spinal cords were collected at 1, 3, 5 and 7-days post-injury for analysis of myelination, neurofilament protein NF200 expression, neuronal cell death, reactive astrocytes (GFAP+ cells), interleukin1β (IL1β) expression, and inducible nitric oxide synthase (iNOS) production in IBA1+ microglia/macrophages. Red-light treatment significantly reduced the cumulative mechanical sensitivity and the hypersensitivity incidence following SCI. This effect was accompanied by significantly reduced neuronal cell death, reduced astrocyte activation and reduced iNOS expression in IBA1+ cells at the level of the injury. However, myelin and NF200 immunoreactivity and IL1β expression in GFAP+ and IBA1+ cells were not altered by red-light treatment. Thus, red-light therapy may represent a useful non-pharmacological approach for treating pain during the subacute period after SCI by decreasing neuronal loss and modulating the inflammatory glial response.

show abstract

Near-infrared light treatment reduces astrogliosis in MPTP-treated monkeys

Cited by 38 publications

References 38 publications

Photobiomodulation and the brain: a new paradigm

Photobiomodulation and the brain: a new paradigm

Retrospective Observational Study and Analysis of Two Different Photobiomodulation Therapy Protocols Combined with Rehabilitation Therapy as Therapeutic Interventions for Canine Degenerative Myelopathy

Red-light (670 nm) therapy reduces mechanical sensitivity and neuronal cell death, and alters glial responses following spinal cord injury in rats

Contact Info

Product

Resources

About